Informations sur le produit
DPM-1001 is a novel, orally available tyrosine phosphatase inhibitor. DPM-1001 prevents the activation of protein phosphatases by inhibiting the enzyme responsible for removing phosphate groups from tyrosine residues. This leads to an accumulation of insulin receptor substrate 1 (IRS1) in cells, which is associated with type 2 diabetes and other metabolic diseases. In addition, DPM-1001 has been shown to inhibit cancer growth in vitro and in vivo, as well as to prevent neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. The chemical structure of DPM-1001 is apigenin linked through a phosphate group to a quinoline moiety. The symptoms of DPM-1001 overdose are nausea, vomiting, diarrhea, abdominal pain, dizziness and headache.
Propriétés chimiques
Question d’ordre technique sur : 3D-WIC17227 DPM-1001
Si vous souhaitez demander un devis ou passer commande, veuillez plutôt ajouter les produits souhaités à votre panier, puis demander un devis ou passer commande à partir de votre panier. C'est une méthode plus rapide, plus économique, et vous pourrez bénéficier des remises disponibles ainsi que d'autres avantages
